Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
TriSalus Life Sciences, Inc. entered into Agreement and Plan of Merger with MedTech Acquisition Corporation valued at Merger with TriSalus surviving as wholly owned subsidiary; TriSalus equity holders receive MTAC comm (effective 2022-11-11).
- Action
- entry
- Agreement
- merger
- Counterparty
- MedTech Acquisition Corporation
- Value
- Merger with TriSalus surviving as wholly owned subsidiary; TriSalus equity holders receive MTAC comm
- Effective
- 2022-11-11
Exact text from the filing
On November 11, 2022, MedTech Acquisition Corporation, a Delaware corporation (“ MTAC ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with MTAC Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of MTAC (“ Merger Sub ”), and TriSalus Life Sciences, Inc., a Delaware corporation (“ TriSalus ”), pursuant to which, subject to the satisfaction or waiver of certain conditions set forth therein, Merger Sub will merge with and into TriSalus (the “ Merger ”), with TriSalus surviving the Merger as a wholly owned subsidiary of MTAC, and with TriSalus’ equity holders receiving shares of MTAC common stock
View on SEC.gov